This case report is about myopericytomatosis, a recently described rare tumor entity with only a dozen cases found in PubMed. Histologically, this tumor is characterized by diffuse infiltration of innumerable discrete myopericytoma-like nodules composed of myoid cells in a perivascular distribution. PDGFRB mutation has been linked to myopericytomatosis as well as other myopericytic tumors. The aim of this paper is to share the clinical presentation and expand the spectrum of genetic findings. We report a case of myopericytomatosis arising around the left ankle of a 73-year-old man. MRI, biopsy, and histopathology were the main diagnostic steps. Targeted next-generation sequencing was carried out to analyze the tumor sample. We performed local excision for tumor mass reduction, as wide resection was impossible a priori based on the delicate anatomical region with important structures in close proximity. Genetic analysis revealed a missense mutation of PDGFRB. PDGFRB alteration seems to play a pathogenic role in myopericytomatosis as highlighted in previously reported cases. Currently, myopericytomatosis is best treated surgically.
Background
Myopericytoma is a benign soft tissue tumor generally arising within the subcutis. It is a painless, slow-growing lesion composed of perivascular smooth muscle cell-like/myoid appearing cells. These oval to spindle-shaped cells are arranged concentrically around numerous blood vessels. According to the current WHO classification, myopericytoma is categorized under pericytic tumors along with myofibroma, angioleiomyoma, and glomus tumor. These tumors show a morphological continuum within the perivascular myoid lineage [1, 2] . We report a case of a recently described tumor entity within the spectrum of pericytic tumors, diffusely located around the ankle joint. Diffuse infiltration of myopericytic lesions is a very rare finding and has only been reported a few times in worldwide literature [3] . According to medical terminology, this phenomenon has been named myopericytomatosis, as the suffix B-osis^conceptualizes an increased or more distributed condition.
Case Presentation
A 73-year-old Caucasian male was referred to our sarcoma center with an ulcerated lump at the outer malleolus of the left foot. The lesion had been present for more than 10 years with slow but constant tumor growth.
By the time of the first consultation at our center, the lesion has already been ulcerated and superinfected as a possible sequel of biopsy and tumor progression (Fig. 1) . Further nodules were palpated at the inner malleolus of the left foot.
The patient seemed to have normal cognitive function, but had been reluctant to seek medical advice for years. He had applied home remedies and strongly believed that topical application of home distilled schnaps would improve the condition.
The referring institution had performed a biopsy of the prominent mass that described a benign, pericytic neoplasm.
Diagnostic Focus and Assessment
Histological examination of the biopsy performed by the referring institution showed bland spindled to ovoid cells arranged around blood vessels lacking nuclear atypia, significant mitotic activity, or necrotic areas. All cells demonstrated a strong smooth muscle actin (SMA) expression by immunohistochemistry and lacked expression of desmin, or epithelial membrane antigen (EMA).
An MRI study described the clinically prominent soft tissue mass at the outer malleolus (5.5 × 4.6 × 3.0 cm) and detected several smaller lesions around the ankle (two masses caudal to the main lesion, several masses dorsal to the calcaneus and the ankle, and two masses medial to the calcaneal tuberosity) (Fig. 2a, b) . On T1-weighted imaging, the lesions were isointense to muscle and hyperintense on T2-weighted imaging. After contrast agent administration, the masses exhibited enhancement mainly in the periphery.
Prior to surgery, rebiopsy was carried out as MRI featured a rather malignant appearance. However, the pathology report confirmed the finding of a diffuse but benign pericytic lesion.
The definite surgical specimen showed typical soft tissue with d i ffu s e i n f i l t r a t i o n of nu m e r o u s va r i a b l e si z e d myopericytoma/myofibroma-like nodules composed of bland spindled to ovoid cells arranged around blood vessels ( Fig. 3a, b) . Nuclear atypia or increased mitotic activities were not seen. By immunohistochemistry, tumor cells were positive for SMA ( Fig. 3c ) and negative for EMA, pan-cytokeratin, desmin, and caldesmon. Hence, myopericytomatosis was confirmed.
Targeted next-generation sequencing was performed on a tumor sample using the regioSARC VEGF panel. This customized panel was used to analyze hot spot mutations in 50 tumor associated genes as well as the full coding sequence of VEGFR1-3, FGFR1, KIT, PDGFRB, RAF1, RET1, TIE2, and TP53. A mutation of PDGFRB was identified. It harbored the missense mutation p.W566R (c.1696 T > C) in exon 12. In addition, mutation of FLT4 was found with a missense mutation at p.R1324L (c.3971 G > T) in exon 30. 
Therapeutic Intervention
The clinical presentation with ulceration, superinfection, and multifocality of the neoplastic disease were considered in decision-making. We offered the patient two surgical options: (1) below knee amputation or (2) tumor reduction of the ulcerated tumor at the outer malleolus with secondary wound closure including negative pressure wound therapy. Theoretically, marginal resection is curative in benign myopericytic lesions. However, tumor masses extended towards important neurovascular bundles on both sides of the ankle, rendering a more aggressive procedure impossible. Moreover, skin coverage after wide resection in this area is challenging and complication rate is high.
The patient gave informed consent to the second option unwilling to lose his foot for the benefit of disease freedom. Hence, surgery with the aim of tumor mass reduction was carried out. The pathology report showed resection margins positive for tumor cells. In other words, R1 resection with tumor reduction was confirmed. The lesions at the medial ankle were left untouched by the surgeon. Given the slowgrowing nature of the lesions and the multimorbidity of the patient, we favored minimal invasiveness and early rehabilitation over more complex procedures with high postoperative complication rates.
Our oncologists offered imatinib facing the non-curative surgical procedure. However, the patient refused any further treatment without giving reasons.
Follow-Up
The postoperative course was uncomplicated with vacuumassisted closure for wound management. On his most recent follow-up examination 9 months after surgery, the patient showed closed wounds apart from a 2-mm defect at the outer malleolus. Clinically, there was no sign of tumor progression. MRI studies are scheduled for further follow-up.
Discussion and Conclusions
In 2017, Hung and Fletcher reported a series of eleven cases of diffuse dermal and/or subcutaneous involvement of myopericytomatous nodules identified out of a collective of over 1000 surgically treated myopericytic lesions [3] . Beyond that, we identified only one more case in current worldwide literature [4] . Clinically, the predilected localization is the lower extremity as seen in eleven of the twelve formerly described patients. In comparison to myopericytoma, these lesions lacked the solid shape and were characterized by numerous discontiguous, microscopic to sub-centimeter nodules of myopericytomatous tumor tissue. The new entity was called myopericytomatosis to highlight the strikingly diffuse growth pattern [3] .
Although infiltrative in its appearance, myopericytomatosis is part of the morphological continuum of benign myopericytic lesions. It is histologically different from rare malignant myopericytoma that exhibits atypical myoid tumor cells with increased mitotic activity. Clinically, malignant myopericytomas develop distant metastatic disease in contrast to local tissue involvement seen in myopericytomatosis [5] .
In the reported series, Hung and Fletcher identified genetic aberrations of the PDGFRB gene using targeted nextgeneration sequencing. PDGFRB mutations were found in four of five cases of myopericytomatosis (3× missense mutation, 1× deletion) and in three of five conventional myopericytomas (2× missense mutation, 1× deletion). They suggested that the PDGFRB mutation status might account for the pathogenetic differences between the two entities [3] .
In our case of myopericytomatosis, the finding of PDGFRB missense mutation supports the possible pathogenic role of this particular gene in disease development. PDGFRB (platelet-derived growth factor receptor β) is a receptor tyrosine kinase involved, e.g., in signaling processes linked to vascular development during embryogenesis. In vitro studies indicated that PDGFRB-expressing pericytes stabilize nascent blood vessels [6] . Mutations of PDGFRB have been found in a number of different pathologies including Penttinen syndrome (syndrome of premature aging) [7] , primary familial brain calcifications [8] , and infantile myofibromatosis [9, 10] . The pleiotropy of the PDGFRB gene accounts for the diverse manifestations in different organ systems.
Our second genetic finding is a missense mutation in the FLT4 gene. It encodes a protein called vascular endothelial growth factor receptor 3 (VEGFR3), which regulates the development and maintenance of the lymphatic system. Mutation has been associated with congenital primary lymphedema [11] . Our patient indeed showed bilateral ankle edemata that have been present for decades. However, no further investigation has been carried out to shed light on the relevance of FLT4 mutation in this case. It remains unclear from the current literature if it represents a pathogenic mutation or rather a variant of uncertain significance (VUS).
Deregulated protein tyrosine kinase activity plays a key role in the pathogenesis of human cancers. Targeted therapy with tyrosine kinase inhibitors (TKIs) had great success in anti-tumor therapy in various cancers. Interestingly, PDGFRB has been therapeutically targeted in a child with refractory multiple infantile myofibromatosis [12, 13] . PDGFRB mutations in familial infantile myofibromatosis were shown to activate the receptor in the absence of a ligand, also supporting the hypothesis that these mutations cause the disease. The activated mutants analyzed in the biochemical study were sensitive to tyrosine kinase inhibitors such as imatinib, nilotinib, and ponatinib [13] . Myopericytomatosis is a rare and benign condition that is best treated surgically. PDGFRB alterations are thought to be central in development of disease. Hence, in cases with limited surgical options (multimorbidity, patient refusal, proximity to neurovascular structures, recurrent disease), additional treatment with TKIs might be of interest. Nevertheless, more studies on efficacy, drug safety, and patient benefit need to be done.
